Ondine Biomedical Inc.

LSE OBI.L

Ondine Biomedical Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -4.31

Ondine Biomedical Inc. Price to Earnings Ratio (P/E) is -4.31 on January 14, 2025, a -19.07% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • Ondine Biomedical Inc. 52-week high Price to Earnings Ratio (P/E) is -2.09 on May 01, 2024, which is 51.53% above the current Price to Earnings Ratio (P/E).
  • Ondine Biomedical Inc. 52-week low Price to Earnings Ratio (P/E) is -4.54 on November 06, 2024, which is -5.50% below the current Price to Earnings Ratio (P/E).
  • Ondine Biomedical Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -3.47.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
Loading...
LSE: OBI.L

Ondine Biomedical Inc.

CEO Ms. Carolyn M. Cross C.F.A., CFA, M.B.A., MBA
IPO Date Dec. 6, 2021
Location Canada
Headquarters 1100 Melville Street
Employees 18
Sector Health Care
Industries
Description

Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company's lead product is Steriwave, a photodisinfection based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces SARS-CoV-2 titre and transmission; a solution for treatment of chronic rhinosinusitis; OND1002, a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and OND1003, a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.

Similar companies

AREC.L

Arecor Therapeutics plc

USD 0.71

0.09%

POLB.L

Poolbeg Pharma PLC

USD 0.06

1.92%

StockViz Staff

January 15, 2025

Any question? Send us an email